Cystinuria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cystinuria, an uncommon condition affecting the transport of amino acids in renal tubules, is characterized by recurrent kidney stone formation primarily composed of cystine. This disorder follows an autosomal recessive inheritance pattern. It is attributed to mutations in the SLC7A9 and SLC3A1 genes, which encode a protein complex that regulates kidney amino acid reabsorption. Genetic alterations in these genes disrupt the function of the protein complex, leading to increased cystine concentration in urine. Clinical presentation mirrors that of obstructive urolithiasis, featuring symptoms such as flank pain, hematuria, vomiting, and fever, with variations observed in pediatric cases, including dysuria, recurrent abdominal pain, and urinary tract infections. Stone analysis remains pivotal for precise diagnosis, the gold standard for identifying kidney stone types, including cystine stones. The current treatment paradigm for cystine stone formers advocates a stepwise approach, commencing with conservative measures. Initial management entails dietary modifications, adequate hydration, and urine alkalization.
·
The prevalence of cystinuria in the United
States is approximately 1 in 7000 individuals; reported rates vary
significantly across different populations, ranging from 1 in 2500 to 1 in
100,000.
Thelansis’s
“Cystinuria Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2023 To 2033" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Cystinuria treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights of Cystinuria across 8
MM market from the centre of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm, and Unmet needs.
Cystinuria
Market Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Cystinuria,
Cystinuria market outlook, Cystinuria competitive landscape, Cystinuria market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment